Verona Pharma plc (NASDAQ: VRNA) was founded in February 2005 as Isis Resources plc. Later in September 2006, the company acquired Rhinopharma Limited of Canada and changed its name to Verona Pharma plc, the company’s headquarters Located in London, UK, with 15 full-time employees (9/30/2018), it is a clinical-stage biopharmaceutical company, mainly researching in the UK and North America, discovering and developing therapeutic drugs for the treatment of respiratory diseases.
Verona Pharma (VRNA):
Verona Pharmaceuticals’ vision is to be a leader in the development and commercialization of innovative treatments to improve the health and quality of life of the millions of people affected by chronic respiratory diseases.
Verona Pharma plc is a clinical-stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutic drugs for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma’s leading product candidate is RPL554, an inhaled bisphosphodiesterase 3 and 4 ((PDE3 and PDE4)) inhibitor, currently in phase II clinical treatment for chronic obstructive pulmonary disease, cystic fibrosis and asthma Experimental phase. RPL554, acts as both a bronchodilator and an anti-inflammatory agent in a single compound. There is currently no treatment for bronchodilators and anti-inflammatory agents in a single compound that can be used to treat respiratory diseases. Verona Pharmaceuticals believes that RPL554 is expected to become the first new type of bronchodilator in the past four decades.
Verona Pharma (VRNA) investment:
Verona Pharma plc (NASDAQ: VRNA) was listed on Nasdaq on 4/27/2017 IPO, with an issue price of $13.50, issuing 5.768 million shares, raising USD 77.868 million, stock code: VRNA.